Is Pegvisomant safe while breastfeeding?
Here is what NIH LactMed, the U.S. National Library of Medicine's authority on medicines and breastfeeding, reports about Pegvisomant. This is a summary of that source — not our own verdict.
Effects on the breastfed infant
A woman with acromegaly was treated with lanreotide Autogel 120 mg monthly, cabergoline 2 mg weekly and pegvisomant 80 mg weekly. She breastfed (extent not stated) her infant and they were followed for 12 years. Her child had normal growth and development.[ 3 ]
Effects on milk supply
Relevant published information was not found as of the revision date.
Levels in milk
Maternal Levels. A woman was being treated during pregnancy for acromegaly with subcutaneous pegvisomant at a dosage that was progressively escalated from 15 mg to 25 mg daily during the course of pregnancy, and presumably postpartum. At an unreported time postpartum, pegvisomant was not detectable ( 50 mcg/L) in breastmilk. The patient's breastmilk growth hormone concentration was 0.6 mcg/L compared to 0.1 mcg/L in 3 breastmilk samples from normal healthy mothers.[ 2 ] Infant Levels. Relevant published information was not found as of the revision date.
Source: NIH LactMed (National Library of Medicine).
Educational summary of an authoritative source — not medical advice. Never start, stop, or change a medicine while breastfeeding without confirming with your doctor.